{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T03:03:36Z","timestamp":1789355016340,"version":"build-2803163510"},"update-to":[{"DOI":"10.1002\/14651858.cd001347","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2016,10,5]],"date-time":"2016-10-05T00:00:00Z","timestamp":1475625600000}}],"reference-count":95,"publisher":"Wiley","issue":"10","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd001347.pub2","type":"journal-article","created":{"date-parts":[[2016,10,12]],"date-time":"2016-10-12T16:38:33Z","timestamp":1476290313000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Bisphosphonates for steroid-induced osteoporosis"],"prefix":"10.1002","volume":"2016","author":[{"given":"Claire S","family":"Allen","sequence":"first","affiliation":[{"name":"University of Alberta; Department of Rheumatology; 562 Heritage Medical Research Centre Edmonton AB Canada T6G 2S2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James HS","family":"Yeung","sequence":"additional","affiliation":[{"name":"University of Alberta; Department of Rheumatology; 562 Heritage Medical Research Centre Edmonton AB Canada T6G 2S2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Vandermeer","sequence":"additional","affiliation":[{"name":"University of Alberta; Department of Pediatrics; 4-496B Edmonton Clinic Health Academy (ECHA) 11405 - 87 Avenue Edmonton AB Canada T6G 1C9"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Homik","sequence":"additional","affiliation":[{"name":"University of Alberta; Department of Medicine; 562 Heritage Medical Research Centre Edmonton AB Canada T6G 2S2"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,10,5]]},"reference":[{"key":"10.1002\/14651858.CD001347.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/j.cgh.2007.05.016","article-title":"A double-blind placebo-controlled study of intravenous clodronate for prevention of steroid-induced bone loss in inflammatory bowel disease","volume":"5","author":"Abitbol","year":"2007","journal-title":"Clinical Gastroenterology & Hepatology"},{"issue":"6","key":"10.1002\/14651858.CD001347.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1056\/NEJM199708073370603","article-title":"Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis","volume":"337","author":"Adachi","year":"1997","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD001347.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/1529-0131(200101)44:1<202::AID-ANR27>3.0.CO;2-W","article-title":"Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial","volume":"44","author":"Adachi","year":"2001","journal-title":"Arthritis & Rheumatism"},{"key":"10.1002\/14651858.CD001347.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/s002239900334","article-title":"Primary prevention of glucocorticoid-induced osteoporosis with intermittent intravenous pamidronate: a randomized trial","volume":"61","author":"Boutsen","year":"1997","journal-title":"Calcified Tissue International"},{"key":"10.1002\/14651858.CD001347.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1359\/jbmr.2001.16.1.104","article-title":"Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone","volume":"16","author":"Boutsen","year":"2001","journal-title":"Journal of Bone & Mineral Research"},{"key":"10.1002\/14651858.CD001347.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1002\/1529-0131(199911)42:11<2309::AID-ANR8>3.0.CO;2-K","article-title":"Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study","volume":"42","author":"Cohen","year":"1999","journal-title":"Arthritis & Rheumatism"},{"key":"10.1002\/14651858.CD001347.pub2-BIB0007|cit7","first-page":"214","article-title":"Evaluation of the efficacy of etidronate therapy in preventing glucocorticoid-induced bone loss in patients with inflammatory rheumatic diseases. A randomized study","volume":"66","author":"Cortet","year":"1999","journal-title":"Revue du Rhumatisme (English Edition)"},{"key":"10.1002\/14651858.CD001347.pub2-BIB0008|cit8","first-page":"675","article-title":"Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis.[Reprint in Ned Tijdschr Geneeskd. 2007 May 26;151(21):1178-85; PMID: 17557758]","volume":"355","author":"Nijs","year":"2006","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD001347.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/S8756-3282(03)00208-4","article-title":"Effects of 4-year treatment with once-weekly clodronate on prevention of corticosteroid-induced bone loss and fractures in patients with arthritis: evaluation with dual-energy X-ray absorptiometry and quantitative ultrasound","volume":"33","author":"Frediani","year":"2003","journal-title":"Bone"},{"key":"10.1002\/14651858.CD001347.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1136\/ard.57.12.724","article-title":"Cyclical etidronate increases bone density in the spine and hip of postmenopausal women receiving long term corticosteroid treatment. A double blind, randomised placebo controlled study","volume":"57","author":"Geusens","year":"1998","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"4","key":"10.1002\/14651858.CD001347.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"260","DOI":"10.3109\/03009742.2012.664647","article-title":"Once-monthly oral ibandronate provides significant improvement in bone mineral density in postmenopausal women treated with glucocorticoids for inflammatory rheumatic diseases: a 12-month, randomized, double-blind, placebo-controlled trial","volume":"41","author":"Hakala","year":"2012","journal-title":"Scandinavian Journal of Rheumatology"},{"key":"10.1002\/14651858.CD001347.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S8756-3282(98)00051-9","article-title":"Clodronate is effective in preventing corticosteroid-induced bone loss among asthmatic patients","volume":"22","author":"Herrala","year":"1998","journal-title":"Bone"},{"key":"10.1002\/14651858.CD001347.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1080\/03009749950154211","article-title":"The prevention of corticosteroid-induced bone loss with intermittent cyclical etidronate","volume":"28","author":"Jenkins","year":"1999","journal-title":"Scandinavian Journal of Rheumatology"},{"key":"10.1002\/14651858.CD001347.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1007\/s00198-005-0037-2","article-title":"Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial","volume":"17","author":"Lems","year":"2006","journal-title":"Osteoporosis International"},{"issue":"5","key":"10.1002\/14651858.CD001347.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"R198","DOI":"10.1186\/ar3170","article-title":"Ibandronate increases cortical bone density in patients with systemic lupus erythematosus on long-term glucocorticoid","volume":"12","author":"Li","year":"2010","journal-title":"Arthritis Research & Therapy"},{"key":"10.1002\/14651858.CD001347.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/thx.53.5.351","article-title":"A double blind placebo controlled study to determine the effects of intermittent cyclical etidronate on bone mineral density in patients on long-term oral corticosteroid treatment","volume":"53","author":"Pitt","year":"1998","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD001347.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1359\/jbmr.2000.15.6.1006","article-title":"Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study","volume":"15","author":"Reid","year":"2000","journal-title":"Journal of Bone & Mineral Research"},{"key":"10.1002\/14651858.CD001347.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1210\/jcem.83.4.4742","article-title":"Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss. Ciblos Study Group","volume":"83","author":"Roux","year":"1998","journal-title":"Journal of Clinical Endocrinology & Metabolism"},{"issue":"1","key":"10.1002\/14651858.CD001347.pub2-BIB0019|cit19","first-page":"8","article-title":"The effect of bisphosphonate on prevention of glucocorticoid-induced osteoporosis","volume":"10","author":"Saadati","year":"2008","journal-title":"Iranian Red Crescent Medical Journal"},{"key":"10.1002\/14651858.CD001347.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1056\/NEJM199807303390502","article-title":"Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis","volume":"339","author":"Saag","year":"1998","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD001347.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1359\/jbmr.2003.18.5.919","article-title":"Prevention and treatment of glucocorticoid-induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium","volume":"18","author":"Sambrook","year":"2003","journal-title":"Journal of Bone & Mineral Research"},{"key":"10.1002\/14651858.CD001347.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/j.1742-1241.1997.tb11489.x","article-title":"Cyclical etidronate increases lumbar spine bone density in patients on long-term glucocorticosteroid therapy","volume":"51","author":"Skingle","year":"1997","journal-title":"International journal of clinical practice"},{"key":"10.1002\/14651858.CD001347.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.3899\/jrheum.081207","article-title":"Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial","volume":"36","author":"Stoch","year":"2009","journal-title":"Journal of Rheumatology"},{"issue":"3","key":"10.1002\/14651858.CD001347.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1001\/archdermatol.2011.354","article-title":"Prevention of glucocorticoid-induced osteoporosis in immunobullous diseases with alendronate: a randomized, double-blind, placebo-controlled study","volume":"148","author":"Tee","year":"2012","journal-title":"Archives of Dermatology"},{"key":"10.1002\/14651858.CD001347.pub2-BIB0025|cit25","first-page":"13","article-title":"Influence of cyclic intravenous pamidronate on proinflammatory monocytic cytokine profiles and bone density in rheumatoid arthritis treated with low dose prednisolone and methotrexate","volume":"19","author":"Offel","year":"2001","journal-title":"Clinical & Experimental Rheumatology"},{"key":"10.1002\/14651858.CD001347.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S0168-8278(97)80048-7","article-title":"Cyclical etidronate in the prevention of bone loss in corticosteroid-treated primary biliary cirrhosis. A prospective, controlled pilot study","volume":"26","author":"Wolfhagen","year":"1991","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD001347.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.3899\/jrheum.080634","article-title":"A comparison of calcium, calcitriol, and alendronate in corticosteroid-treated premenopausal patients with systemic lupus erythematosus","volume":"35","author":"Yeap","year":"2008","journal-title":"Journal of Rheumatology"},{"issue":"4","key":"10.1002\/14651858.CD001347.pub2-BIB0028|cit28","first-page":"567","article-title":"Effects of monthly intramuscular neridronate in rheumatic patients in chronic treatment with low-dose glucocorticoids","volume":"27","author":"Benucci","year":"2009","journal-title":"Clinical and Experimental Rheumatology"},{"key":"10.1002\/14651858.CD001347.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1093\/ndt\/gfl567","article-title":"Risedronate, an effective treatment for glucocorticoid-induced bone loss in CKD patients with or without concomitant active vitamin D (PRIUS-CKD)","volume":"22","author":"Fujii","year":"2007","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1002\/14651858.CD001347.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"219","DOI":"10.2739\/kurumemedj.47.219","article-title":"Efficacy of intermittent etidronate therapy for corticosteroid-induced osteoporosis in patients with diffuse connective tissue disease","volume":"47","author":"Jinnouchi","year":"2000","journal-title":"Kurume Medical Journal"},{"key":"10.1002\/14651858.CD001347.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1093\/ndt\/gfl568","article-title":"Effect of risedronate on high-dose corticosteroid-induced bone loss in patients with glomerular disease","volume":"22","author":"Kikuchi","year":"2007","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD001347.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/j.1365-2036.2008.03899.x","article-title":"Clinical trial: comparison of alendronate and alfacalcidol in glucocorticoid-associated osteoporosis in patients with ulcerative colitis","volume":"29","author":"Kitazaki","year":"2009","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"10.1002\/14651858.CD001347.pub2-BIB0033|cit33","first-page":"163","article-title":"Etidronate prevents high dose glucocorticoid induced bone loss in premenopausal individuals with systemic autoimmune diseases","volume":"31","author":"Nakayamada","year":"2004","journal-title":"Journal of Rheumatology"},{"key":"10.1002\/14651858.CD001347.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.3899\/jrheum.080168","article-title":"Alendronate protects premenopausal women from bone loss and fracture associated with high-dose glucocorticoid therapy","volume":"35","author":"Okada","year":"2008","journal-title":"Journal of Rheumatology"},{"key":"10.1002\/14651858.CD001347.pub2-BIB0035|cit35","first-page":"2673","article-title":"Effect of intermittent cyclical etidronate therapy on corticosteroid induced osteoporosis in Japanese patients with connective tissue disease: 3 year follow up","volume":"30","author":"Sato","year":"2003","journal-title":"Journal of Rheumatology"},{"issue":"3","key":"10.1002\/14651858.CD001347.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3109\/s10165-008-0055-y","article-title":"Effect of alendronate on glucocorticoid-induced osteoporosis in Japanese women with systemic autoimmune diseases: versus alfacalcidol","volume":"18","author":"Takeda","year":"2008","journal-title":"Modern Rheumatology"},{"issue":"19","key":"10.1002\/14651858.CD001347.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.2169\/internalmedicine.49.3707","article-title":"Risedronate therapy for the prevention of steroid-induced osteoporosis in patients with minimal-change nephrotic syndrome","volume":"49","author":"Takei","year":"2010","journal-title":"Internal Medicine"},{"key":"10.1002\/14651858.CD001347.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1191\/0961203305lu2149oa","article-title":"Oral pamidronate prevents high-dose glucocorticoid-induced lumbar spine bone loss in premenopausal connective tissue disease (mainly lupus) patients","volume":"14","author":"Toukap","year":"2005","journal-title":"Lupus"},{"issue":"11","key":"10.1002\/14651858.CD001347.pub2-BIB0039|cit39","first-page":"1844","article-title":"Activate form vitamin D3 or bisphosphonate in glucocorticoid-induced osteoporosis","volume":"16","author":"Imanishi","year":"2006","journal-title":"Clinical Calcium"},{"issue":"4","key":"10.1002\/14651858.CD001347.pub2-BIB0040|cit40","first-page":"666","article-title":"The clinical benefits to bone mineral density were shown by cyclical oral etidronate administration in steroid induced osteoporosis","volume":"42","author":"Nakamura","year":"2002","journal-title":"Ryumachi"},{"issue":"10","key":"10.1002\/14651858.CD001347.pub2-BIB0041|cit41","first-page":"1740","article-title":"Pharmacological treatment of other types of secondary osteoporosis","volume":"73","author":"Okazaki","year":"2015","journal-title":"Nippon Rinsho - Japanese Journal of Clinical Medicine"},{"key":"10.1002\/14651858.CD001347.pub2-BIB0042|cit42","first-page":"17","article-title":"The bone mineral density effects of calcitonin and alendronate combined therapy in patients with rheumatoid arthritis","volume":"10","author":"Ozoran","year":"2007","journal-title":"Asia Pacific League of Associations for Rheumatology Journal of Rheumatology"},{"issue":"10","key":"10.1002\/14651858.CD001347.pub2-BIB0043|cit43","first-page":"1733","article-title":"Glucocorticoid-induced osteoporosis","volume":"73","author":"Suzuki","year":"2015","journal-title":"Nippon Rinsho - Japanese Journal of Clinical Medicine"},{"key":"10.1002\/14651858.CD001347.pub2-BIB0044|cit44","unstructured":"A phase III randomized study of zoledronate bisphosphonate therapy for the prevention of bone loss in men with prostate cancer receiving long-term androgen deprivation Ongoing study March 2003"},{"key":"10.1002\/14651858.CD001347.pub2-BIB0045|cit45","unstructured":"ZEST II for osteoporotic fracture prevention Ongoing study January 2016"},{"key":"10.1002\/14651858.CD001347.pub2-BIB0046|cit46","unstructured":"Drug therapy for the prevention of glucocorticoid induced osteoporosis in elderly patients: teriparatide or bisphosphonates? Ongoing study"},{"key":"10.1002\/14651858.CD001347.pub2-BIB0047|cit47","unstructured":"Efficacy of once every four week oral minodronate in patients with glucocorticoid-induced osteoporosis after switching from weekly oral bisphosphonate Ongoing study"},{"key":"10.1002\/14651858.CD001347.pub2-BIB0048|cit48","unstructured":"Efficacy of a human anti-RANKL antibody (Denosumab) on prevention of steroid-induced osteoporosis in patients with autoimmune hepatitis (AIH) Ongoing study"},{"key":"10.1002\/14651858.CD001347.pub2-BIB0049|cit49","unstructured":"Glucocorticoid-induced osteoporosis treated with bisphosphonate and denosumab Ongoing study"},{"issue":"12","key":"10.1002\/14651858.CD001347.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"5258\u201365","DOI":"10.1210\/jc.2010-1571","article-title":"Cumulative alendronate dose and the long-term absolute risk of subtrochanteric and diaphyseal femur fractures: a register-based national cohort analysis","volume":"95","author":"Abrahamsen","year":"2010","journal-title":"Journal of Clinical Endocrinology & Metabolism"},{"key":"10.1002\/14651858.CD001347.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group","volume":"348","author":"Black","year":"1996","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD001347.pub2-BIB0052|cit52","unstructured":"Brant R Inference for Proportions: Comparing Two Independent Samples 2014"},{"key":"10.1002\/14651858.CD001347.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1007\/s00198-007-0394-0","article-title":"Glucocorticoid-induced osteoporosis: pathophysiology and therapy","volume":"18","author":"Canalis","year":"2007","journal-title":"Osteoporosis International"},{"key":"10.1002\/14651858.CD001347.pub2-BIB0054|cit54","unstructured":"Cates C Visual Rx Software. 2008"},{"key":"10.1002\/14651858.CD001347.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/jbmr.5650070214","article-title":"Incidence of clinically diagnosed vertebral fractures: a population-based study in Rochester, Minnesota, 1985-1989","volume":"7","author":"Cooper","year":"1992","journal-title":"Journal of Bone and Mineral Research"},{"key":"10.1002\/14651858.CD001347.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0002-9343(01)01124-X","article-title":"Improvement in Spine Bone Density and Reduction in Risk of Vertebral Fractures during Treatment with Antiresorptive Drugs","volume":"112","author":"Cummings","year":"2002","journal-title":"American Journal of Medicine"},{"issue":"8","key":"10.1002\/14651858.CD001347.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1002\/art.21194","article-title":"Longitudinal patterns in the prevention of osteoporosis in glucocorticoid-treated patients","volume":"52","author":"Curtis","year":"2005","journal-title":"Arthritis & Rheumatism"},{"key":"10.1002\/14651858.CD001347.pub2-BIB0058|cit58","unstructured":"Deeks JJ Higgins JPT Altman DG (editors) Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"12","key":"10.1002\/14651858.CD001347.pub2-BIB0059|cit59","first-page":"2544\u201350","article-title":"A retrospective analysis of all atypical femur fractures seen in a large California HMO from the years 2007 to 2009","volume":"27","author":"Dell","year":"2012","journal-title":"Journal of Bone and Mineral Research"},{"issue":"12","key":"10.1002\/14651858.CD001347.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/S1701-2163(16)34026-9","article-title":"Does treatment with bisphosphonates endanger the human pregnancy?","volume":"30","author":"Djokanovic","year":"2008","journal-title":"Journal of Obstetrics and Gynaecology Canada"},{"issue":"12","key":"10.1002\/14651858.CD001347.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1007\/s00198-005-2016-z","article-title":"Practice patterns in patients at risk for glucocorticoid-induced osteoporosis","volume":"16","author":"Feldstein","year":"2005","journal-title":"Osteoporosis International"},{"issue":"9","key":"10.1002\/14651858.CD001347.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/jbmr.5650080915","article-title":"Vertebral fracture assessment using a semiquantitative technique","volume":"8","author":"Genant","year":"1993","journal-title":"Journal of Bone and Mineral Research"},{"issue":"7","key":"10.1002\/14651858.CD001347.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1002\/jbmr.5650110716","article-title":"Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis The Study of Osteoporotic Fractures Research Group","volume":"11","author":"Genant","year":"1996","journal-title":"Journal of Bone and Mineral Research"},{"issue":"3","key":"10.1002\/14651858.CD001347.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/0009-9236(95)90245-7","article-title":"Studies on the oral availablility of alendronate","volume":"58","author":"Gertz","year":"1995","journal-title":"Clinical Pharmacology & Therapeutics"},{"key":"10.1002\/14651858.CD001347.pub2-BIB0065|cit65","unstructured":"GRADE Working Group, McMaster University GRADEpro GDT 2015"},{"issue":"11","key":"10.1002\/14651858.CD001347.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1002\/acr.20295","article-title":"American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis","volume":"62","author":"Grossman","year":"2010","journal-title":"Arthritis Care and Research"},{"issue":"7414","key":"10.1002\/14651858.CD001347.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD001347.pub2-BIB0068|cit68","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD001347.pub2-BIB0069|cit69","unstructured":"Higgins JPT Altman DG Sterne JAC (editors) Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD001347.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3310\/hta11070","article-title":"Glucocorticoid-induced osteoporosis: a systematic review and cost\u2013utility analysis","volume":"11","author":"Kanis","year":"2007","journal-title":"Health Technology Assessment"},{"key":"10.1002\/14651858.CD001347.pub2-BIB0071|cit71","first-page":"518\u201323","article-title":"Assessing vertebral fractures: National Osteoporosis Working Group on Vertebral Fractures","volume":"10","author":"Kiel","year":"1995","journal-title":"Journal of Bone and Mineral Research"},{"key":"10.1002\/14651858.CD001347.pub2-BIB0072|cit72","unstructured":"Kleerekoper M Parfitt AM Ellis BI Measurements of vertebral fracture rates in osteoporosis Proceedings of the Copenhagen International Symposium on Osteoporosis Copenhagen: AalbergStiftsbogtrykkeri 103 109"},{"issue":"3","key":"10.1002\/14651858.CD001347.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"276\u201381","DOI":"10.1093\/fampra\/cmu088","article-title":"Increased risk for atypical fractures associated with bisphosphonate use","volume":"32","author":"Lee","year":"2015","journal-title":"Family Practice"},{"issue":"9","key":"10.1002\/14651858.CD001347.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1007\/s00198-012-1958-1","article-title":"A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis","volume":"23","author":"Lekamwasam","year":"2012","journal-title":"Osteoporosis International"},{"issue":"8","key":"10.1002\/14651858.CD001347.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.autrev.2010.03.002","article-title":"Bisphosphonates in patients with autoimmune rheumatic diseases: can they be used in women of childbearing age?","volume":"9","author":"Losada","year":"2010","journal-title":"Autoimmunity Reviews"},{"key":"10.1002\/14651858.CD001347.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1093\/rheumatology\/kes079","article-title":"Quality assurance study of the use of preventative therapies in glucocorticoid-induced osteoporosis in early inflammatory arthritis: results from the CATCH cohort","volume":"51","author":"McKeown","year":"2012","journal-title":"Rheumatology"},{"key":"10.1002\/14651858.CD001347.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/BF01623271","article-title":"Prevalence and incidence of vertebral deformities","volume":"3","author":"Melton","year":"1993","journal-title":"Osteoporosis International"},{"key":"10.1002\/14651858.CD001347.pub2-BIB0078|cit78","first-page":"335\u201349","article-title":"A newly developed spine deformity index (SDI) to quantitate vertebral crush fractures in patients with osteoporosis","volume":"3","author":"Minne","year":"1988","journal-title":"Bone Mineral"},{"key":"10.1002\/14651858.CD001347.pub2-BIB0079|cit79","unstructured":"National Osteoporosis Foundation Clinician\u2019s Guide to Prevention and Treatment of Osteoporosis Washington, DC: National Osteoporosis Foundation; 2014"},{"key":"10.1002\/14651858.CD001347.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"103\u201310","DOI":"10.1016\/j.bone.2011.01.003","article-title":"Safety of Bisphosphonates","volume":"49","author":"Pazianas","year":"2011","journal-title":"Bone"},{"key":"10.1002\/14651858.CD001347.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"1253\u201363","DOI":"10.1016\/S0140-6736(09)60250-6","article-title":"Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial","volume":"373","author":"Reid","year":"2009","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD001347.pub2-BIB0082|cit82","unstructured":"Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2014"},{"issue":"3","key":"10.1002\/14651858.CD001347.pub2-BIB0083|cit83","first-page":"269\u201373","article-title":"Mineral loss in cortical and trabecular bone during high-dose prednisone treatment","volume":"36","author":"Rickers","year":"1984","journal-title":"Calcified Tissue International"},{"key":"10.1002\/14651858.CD001347.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1196\/annals.1402.089","article-title":"Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy","volume":"1117","author":"Russell","year":"2007","journal-title":"Annals of the New York Academy of Sciences"},{"key":"10.1002\/14651858.CD001347.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0889-8529(02)00064-6","article-title":"Glucocorticoid-induced osteoporosis","volume":"32","author":"Saag","year":"2003","journal-title":"Endocrinology and Metabolism Clinics of North America"},{"key":"10.1002\/14651858.CD001347.pub2-BIB0086|cit86","first-page":"289\u201395","article-title":"Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate","volume":"50","author":"Sambrook","year":"2012","journal-title":"Bone"},{"key":"10.1002\/14651858.CD001347.pub2-BIB0087|cit87","unstructured":"Sch\u00fcnemann HJ Oxman AD Higgins JPT Vist GE Glasziou P Guyatt GH Chapter 11: Presenting results and \u2018Summary of findings' tables. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD001347.pub2-BIB0088|cit88","unstructured":"Sch\u00fcnemann HJ Oxman AD Vist GE Higgins JPT Deeks JJ Glasziou P Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 www.handbook.cochrane.org"},{"key":"10.1002\/14651858.CD001347.pub2-BIB0089|cit89","unstructured":"Sch\u00fcnemann H Bro\u017cek J Guyatt G Oxman A (editors) GRADE handbook for grading quality of evidence and strength of recommendations. Updated October 2013. The GRADE Working Group, 2013 Available from guidelinedevelopment.org\/handbook"},{"key":"10.1002\/14651858.CD001347.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s00198-003-1548-3","article-title":"Oral glucocorticoid use is associated with an increased risk of fracture","volume":"15","author":"Steinbuch","year":"2004","journal-title":"Osteoporosis International"},{"key":"10.1002\/14651858.CD001347.pub2-BIB0091|cit91","first-page":"249","article-title":"Radiological aspects","volume-title":"Osteoporosis: etiology, diagnosis, and management","author":"Kuijk","year":"1995"},{"key":"10.1002\/14651858.CD001347.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s001980200108","article-title":"The Epidemiology of Corticosteroid-Induced Osteoporosis: a Meta-analysis","volume":"13","author":"Staa","year":"2002","journal-title":"Osteoporosis International"},{"key":"10.1002\/14651858.CD001347.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.jclinepi.2005.08.017","article-title":"A systematic review identifies a lack of standardization in methods for handling missing variance data","volume":"59","author":"Wiebe","year":"2006","journal-title":"Journal of Clinical Epidemiology"},{"issue":"1 Art. No.: CD0","key":"10.1002\/14651858.CD001347.pub2-BIB0094|cit94","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001347","article-title":"Bisphosphonates for steroid induced osteoporosis","author":"Homik","year":"1999","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD001347.pub2-BIB0095|cit95","first-page":"1148","article-title":"A meta-analysis on the use of bisphosphonates in corticosteroid induced osteoporosis","volume":"26","author":"Homik","year":"1999","journal-title":"Journal of Rheumatology"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD001347.pub2\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T02:32:11Z","timestamp":1789353131000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD001347.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Musculoskeletal Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2016,10,5]]},"references-count":95,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2016,10]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd001347.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,5]]}}}